JPH0144179B2 - - Google Patents

Info

Publication number
JPH0144179B2
JPH0144179B2 JP60121370A JP12137085A JPH0144179B2 JP H0144179 B2 JPH0144179 B2 JP H0144179B2 JP 60121370 A JP60121370 A JP 60121370A JP 12137085 A JP12137085 A JP 12137085A JP H0144179 B2 JPH0144179 B2 JP H0144179B2
Authority
JP
Japan
Prior art keywords
formula
acid
compounds
compound
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP60121370A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6133163A (ja
Inventor
Jooji Batsukusutaa Maachin
Reginarudo Erufuitsuku Arubaato
Ainsurii Miraa Arisuteaa
Aran Sooyaa Debitsudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10505597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0144179(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of JPS6133163A publication Critical patent/JPS6133163A/ja
Publication of JPH0144179B2 publication Critical patent/JPH0144179B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP12137085A 1979-06-01 1985-06-04 トリアジン誘導体製造用の新規中間体化合物 Granted JPS6133163A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7919257 1979-06-01
GB7919257 1979-06-01

Publications (2)

Publication Number Publication Date
JPS6133163A JPS6133163A (ja) 1986-02-17
JPH0144179B2 true JPH0144179B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-09-26

Family

ID=10505597

Family Applications (2)

Application Number Title Priority Date Filing Date
JP7158080A Granted JPS5625169A (en) 1979-06-01 1980-05-30 Triazine derivative
JP12137085A Granted JPS6133163A (ja) 1979-06-01 1985-06-04 トリアジン誘導体製造用の新規中間体化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP7158080A Granted JPS5625169A (en) 1979-06-01 1980-05-30 Triazine derivative

Country Status (30)

Country Link
US (2) US4486354A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0021121B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS5625169A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR227521A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT370097B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU530999B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG60427B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1112643A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS234018B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ384891A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD151309A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK153787C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8104993A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI67844C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP19960470B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR68380B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU182086B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE49823B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL60201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1147087B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9202962A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8500062A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL950007I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ193890A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL124029B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (1) SU1055331A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA5576A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU145680A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA803250B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZW (1) ZW12980A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311701A (en) * 1979-08-16 1982-01-19 Barbara Roth Treatment of convulsions with triazines
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4972496A (en) * 1986-07-25 1990-11-20 Grid Systems Corporation Handwritten keyboardless entry computer system
FI895821A7 (fi) 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
GB2257363B (en) * 1991-01-30 1994-09-28 Wellcome Found Water dispersible tablets containing acyclovir
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
YU48573B (sh) * 1992-06-12 1998-12-23 The Wellcome Foundation Ltd. Upotreba 3,5-diamino-6-(2,3-dihlorofenil)-1,2,4-triazin izetionata kao sredstva protiv zavisnosti, tolerancije i osetljivosti na lekove
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
ES2177672T3 (es) * 1994-12-30 2002-12-16 Wellcome Found Procedimiento para preparacion de lamotrigina.
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6202491B1 (en) 1997-07-22 2001-03-20 Skf Condition Monitoring, Inc. Digital vibration coupling stud
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
CA2334937C (en) * 1998-12-14 2004-09-21 Torrent Pharmaceuticals Ltd. An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
IN183150B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1998-12-14 1999-09-25 Torrent Pharmaceuticals Ltd
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
AU4334900A (en) * 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
WO2001049669A1 (en) * 2000-01-03 2001-07-12 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
CZ20031387A3 (cs) 2000-11-30 2004-04-14 Pfizer Products Inc. Farmaceutický prostředek, kterým je směs agonistů gama-aminomáselné kyseliny a inhibitorů aldózreduktázy
AP2001002360A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors.
JP2004526714A (ja) * 2001-02-27 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド ラモトリジンの新しい結晶形およびそれらの調製方法
BRPI0212298B8 (pt) 2001-09-03 2021-05-25 Newron Pharm Spa composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
AU2003234240A1 (en) * 2002-04-23 2003-11-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
US7521553B2 (en) * 2003-03-17 2009-04-21 Hetero Drugs Limited Crystalline forms of lamotrigine
WO2004085426A1 (en) 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
JP5646126B2 (ja) 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
JP2007537151A (ja) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
WO2006027052A2 (en) * 2004-09-10 2006-03-16 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
KR20080050511A (ko) 2005-09-23 2008-06-05 얀센 파마슈티카 엔.브이. 테트라하이드로-사이클로펜틸 피라졸 카나비노이드모듈레이터
CN101312725B (zh) * 2005-09-23 2012-01-11 詹森药业有限公司 六氢-环辛四烯并吡唑大麻素调节剂
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
CN101312726A (zh) * 2005-09-23 2008-11-26 詹森药业有限公司 六氢-环庚三烯并吡唑大麻素调节剂
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2007092456A2 (en) * 2006-02-03 2007-08-16 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007122638A2 (en) * 2006-04-26 2007-11-01 Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. An improved process for preparation of lamotrigine intermediates
WO2007138075A1 (en) * 2006-05-31 2007-12-06 Calaire Chimie Sas Method for preparing lamotrigine and its intermediate 2,3-dichlorobenzoyl chloride
GB0613836D0 (en) * 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
US20120142919A1 (en) 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
EP2054396A1 (en) * 2006-08-14 2009-05-06 Lonza Ag A process for the preparation of lamotrigine
EP2129381A1 (en) * 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
GB0800741D0 (en) * 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2010248943B2 (en) 2009-05-13 2015-05-21 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
US20100297195A1 (en) 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471729A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US20110052686A1 (en) * 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
CN115737651A (zh) * 2015-06-12 2023-03-07 格林威治大学 作为干扰素-γ抑制剂的三嗪衍生物
LT3554490T (lt) 2016-12-16 2022-04-25 Idorsia Pharmaceuticals Ltd Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) * 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
AT190941B (de) * 1954-09-22 1957-07-25 Chemie Linz Ag Verfahren zur Herstellung neuer Guanylhydrazone
US2952677A (en) * 1956-10-01 1960-09-13 Ici Ltd Aminoguanadine compounds
BE663481A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1964-05-05
BE722109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1967-10-12 1969-04-10
GB1223491A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
US4311701A (en) * 1979-08-16 1982-01-19 Barbara Roth Treatment of convulsions with triazines

Also Published As

Publication number Publication date
US4486354A (en) 1984-12-04
NZ193890A (en) 1984-07-06
EP0021121B1 (en) 1983-05-11
ES491998A0 (es) 1981-05-16
US4602017A (en) 1986-07-22
IT8048848A0 (it) 1980-05-30
AU566870B2 (en) 1987-11-05
PL224633A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-02-13
ZA803250B (en) 1982-01-27
GEP19960470B (en) 1996-08-29
ZW12980A1 (en) 1982-01-06
IL60201A (en) 1984-05-31
FI801758A7 (fi) 1980-12-02
EP0021121A1 (en) 1981-01-07
AT370097B (de) 1983-02-25
MY8500062A (en) 1985-12-31
SU1055331A3 (ru) 1983-11-15
AU5890680A (en) 1980-12-04
DK153787C (da) 1989-01-16
IE49823B1 (en) 1985-12-25
DD151309A5 (de) 1981-10-14
IE801126L (en) 1980-12-01
JPH0144706B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-09-29
PL124029B1 (en) 1982-12-31
JPS5625169A (en) 1981-03-10
CZ384891A3 (en) 1993-10-13
ES8104993A1 (es) 1981-05-16
CS234018B2 (en) 1985-03-14
BG60427B2 (bg) 1995-03-31
ATA289680A (de) 1982-07-15
HU182086B (en) 1983-12-28
UA5576A1 (uk) 1994-12-28
AR227521A1 (es) 1982-11-15
GR68380B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-12-28
DK153787B (da) 1988-09-05
EP0059987B1 (en) 1985-08-14
IL60201A0 (en) 1980-07-31
CA1112643A (en) 1981-11-17
FI67844C (fi) 1985-06-10
NL950007I2 (nl) 1997-02-03
AU530999B2 (en) 1983-08-04
MX9202962A (es) 1992-07-01
NL950007I1 (nl) 1995-06-16
IT1147087B (it) 1986-11-19
JPS6133163A (ja) 1986-02-17
DK233880A (da) 1980-12-02
FI67844B (fi) 1985-02-28
EP0059987A1 (en) 1982-09-15
YU145680A (en) 1983-02-28

Similar Documents

Publication Publication Date Title
JPH0144179B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK279988B6 (sk) Pyrimidíny, spôsob ich výroby, farmaceutický prost
US4649139A (en) 1,2,4-triazines
JPS6018658B2 (ja) １−（４−フエノキシ−フエニル）−１，３，５−トリアジン誘導体の製造方法
US4560687A (en) Substituted aromatic compounds
KR920002130B1 (ko) 1-[4-(벤조티아-또는-옥사졸-2-일티오-또는-2-일옥시)페닐]-1,3,5-트리아진-2,4,6-(1h,3h,5h)-트리온의 제조방법
US4173631A (en) 7-Methyl-8-methylamino-10-(1'-D-ribityl)isoalloxazine
EP0086502B1 (en) Substituted aromatic triazines
JP3873173B2 (ja) ビス−２−アミノピリジン類、その製造方法及び寄生虫感染を制御するためのその用途
EP0098589A1 (en) Quinazoline derivatives which are active against coccidiosis
EP0665014B1 (de) 3-Benzoyl-3,7-diazabicyclo(3,3,1)nonan-Verbindungen mit anti-arrhythmischer Wirkung
US5434157A (en) 6-aryl pyrimidine compounds and method for treating viral infections and inducing interferon production
EP0215200A2 (en) Use of sulfanilamido quinoxalines in the treatment of neoplastic diseases
US4315003A (en) Compositions containing azo compounds and use thereof for therapeutic treatment
JPH03261783A (ja) １，２，４―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤
CA1133938A (en) Substituted aromatic compounds
CN101068597B (zh) 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
JPH04270223A (ja) 療法的に活性なオルガノシラン誘導体を含む医薬組成物およびその調製方法
JPH0251423B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5813525B2 (ja) 抗コクシジウム剤
TW200530239A (en) Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist